Short-term effect of oral treatment with miglustat in type 1 Gaucher disease.

被引：0
|
作者：
Giraldo, P
Alonso, D
Acedo, M
Franco, R
Barez, A
Corrales, A
Serrano, D
Roldan, V
Latre, P
Alfonso, P
Pocovi, M
机构：
[1] Miguel Servet Univ Hosp, Zaragoza, Spain
[2] Virgen Rocio Univ Hosp, Seville, Spain
[3] Vega Baja Hosp, Alicante, Spain
[4] Punta Europa Univ Hosp, Cadiz, Spain
[5] Ntra Sra Sansoles Hosp, Avila, Spain
[6] Virgen Concha Hosp, Zamora, Spain
[7] Gen Hosp, Alicante, Spain
[8] San Vicente Hosp, Alicante, Spain
[9] Spanish Fdn Study & Therapy Gaucher Dis, FEETEG, Zaragoza, Spain
[10] Inst Aragones Hlth Sci, I & CS, Zaragoza, Spain
[11] Univ Zaragoza, Zaragoza, Spain
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.2235.2235
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2235
引用
收藏
页码：629A / 630A
页数：2
相关论文
共 50 条
  • [31] Effect of miglustat on bone disease in adults with type 1 Gaucher disease:: A pooled analysis of three multinational, open-label studies
    Pastores, Gregory M.
    Elstein, Deborah
    Hrebicek, Martin
    Zimran, Ari
    CLINICAL THERAPEUTICS, 2007, 29 (08) : 1645 - 1654
  • [32] Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project
    Giraldo, Pilar
    Alfonso, Pilar
    Atutxa, Koldo
    Fernandez-Galan, Maria A.
    Barez, Abelardo
    Franco, Rafael
    Alonso, Dora
    Martin, Alejandro
    Latre, Paz
    Pocovi, Miguel
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1771 - 1775
  • [33] Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy
    Canda, Ebru
    Kose, Melis
    Kagnici, Mehtap
    Ucar, Sema Kalkan
    Sozmen, Eser Y.
    Coker, Mahmut
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 : 180 - 184
  • [34] Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study
    Kuter, David J.
    Mehta, Atul
    Hollak, Carla E. M.
    Giraldo, Pilar
    Hughes, Derralynn
    Belmatoug, Nadia
    Brand, Monika
    Muller, Audrey
    Schaaf, Berthold
    Giorgino, Ruben
    Zimran, Ari
    BLOOD CELLS MOLECULES AND DISEASES, 2013, 51 (02) : 116 - 124
  • [35] Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease
    Elstein, D
    Hollak, C
    Aerts, JMFG
    van Weely, S
    Maas, M
    Cox, TM
    Lachmann, RH
    Hrebicek, M
    Platt, FM
    Butters, TD
    Dwek, RA
    Zimran, A
    JOURNAL OF INHERITED METABOLIC DISEASE, 2004, 27 (06) : 757 - 766
  • [36] Immune thrombocytopenia in type I Gaucher disease.
    Napso, Tina
    Bonstein, Lilach
    Rosenbaum, Hanna
    BLOOD, 2007, 110 (11) : 939A - 939A
  • [37] Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution
    Machaczka, Maciej
    Hast, Robert
    Dahlman, Ingrid
    Lerner, Richard
    Klimkowska, Monika
    Engvall, Martin
    Hagglund, Hans
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2012, 117 (01) : 28 - 34
  • [38] Preliminary study of the chaperone effect on mutated glucocerebrosidases as a treatment for Gaucher disease.
    Sanchez-Olle, G.
    Egido-Gabas, M.
    Duque, J.
    Casas, J.
    Chabas, A.
    Vilageliu, L.
    Grinberg, D.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 374 (04) : 344 - 345
  • [39] Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement
    Elstein, Deborah
    Dweck, Altoon
    Attias, Drorit
    Hadas-Halpern, Irith
    Zevin, Shoshana
    Altarescu, Gheona
    Aerts, Johannes F. M. G.
    van Weely, Sonja
    Zimran, Ari
    BLOOD, 2007, 110 (07) : 2296 - 2301
  • [40] The effect of short-term oral treatment with omeprazole or pantoprazole on the function of polymorphonuclear neutrophils
    Kostrzewska, Maja
    Garley, Marzena
    Ratajczak-Wrona, Wioletta
    Jablonska, Ewa
    Jamiolkowski, Jacek
    Dabrowski, Andrzej
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2017, 95 (06) : 675 - 680
12345